“LHRH therapies are not going away. They are the standard of care,” says E. David Crawford, MD.
As part of the Urology Times' 50th Anniversary Innovation Celebration, E. David Crawford, MD, discusses the development of luteinizing hormone-releasing hormone (LHRH) agonists and antagonists in prostate cancer. Crawford is a professor of urology at the University of California, San Diego.
Study finds disparities in management of mCSPC
April 17th 2024“These findings suggest that guideline recommended treatment intensification remains low for patients with mCSPC in both Medicare and the Veterans Health Administration, but especially for Black patients,” says Daniel J. George, MD.